表紙:特発性肺線維症:パイプライン製品の分析
市場調査レポート
商品コード
232804

特発性肺線維症:パイプライン製品の分析

Idiopathic Pulmonary Fibrosis (Respiratory) - Drugs In Development, 2021

出版日: | 発行: Global Markets Direct | ページ情報: 英文 697 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.72円
特発性肺線維症:パイプライン製品の分析
出版日: 2021年08月30日
発行: Global Markets Direct
ページ情報: 英文 697 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

特発性肺線維症(IPF)は、肺の孤立性の進行性疾患です。空咳、息切れ(特に運動中/運動後)、持続的な疲労、体重減少などの症状が見られます。治療は、抗酸化剤、生物学的反応修飾物質、抗線維化剤、抗凝固剤などが含まれます。

当レポートでは、特発性肺線維症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

I特発性肺線維症 - 概要

I特発性肺線維症 - 治療薬の開発

  • パイプラインの概要
  • 企業別のパイプライン動向
  • 大学・研究機関別のパイプライン動向
  • 企業で開発中の製品
  • 大学・研究機関で開発中の製品

I特発性肺線維症 - 治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

I特発性肺線維症の治療薬開発に従事している企業

  • AdAlta Ltd
  • Aeolus Pharmaceuticals Inc
  • Allinky Biopharma
  • apceth Biopharma GmbH
  • Apellis Pharmaceuticals Inc
  • 旭化成ファーマ
  • aTyr Pharma Inc
  • Biogen Inc
  • Bioneer Corp
  • BLR Bio LLC
  • Bristol-Myers Squibb Company
  • Celgene Corp
  • Celldex Therapeutics Inc
  • Chiesi Farmaceutici SpA
  • Compugen Ltd
  • Cynata Therapeutics Ltd
  • F. Hoffmann-La Roche Ltd
  • FibroGen Inc
  • FibroStatin SL
  • Galapagos NV
  • GenKyoTex SA
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd
  • Global Blood Therapeutics Inc
  • GNI Group Ltd
  • Histocell SL
  • iBio Inc
  • Inventiva
  • Isarna Therapeutics GmbH
  • Kadmon Corp LLC
  • Kasiak Research Pvt Ltd
  • Kyorin Pharmaceutical Co Ltd
  • Lung Therapeutics Inc
  • Merck & Co Inc
  • miRagen Therapeutics Inc
  • MorphoSys AG
  • Nuevolution AB
  • Pharmaxis Ltd
  • Promedior Inc
  • ProMetic Life Sciences Inc
  • Pulmatrix Inc
  • Re-Pharm Ltd
  • Redx Pharma Plc
  • Respira Therapeutics Inc
  • Ribomic Inc
  • Saje Pharma LLC
  • Samumed LLC
  • Sanofi
  • Sorrento Therapeutics Inc
  • SPR Biosciences LLC
  • Therabron Therapeutics Inc
  • Unity Biotechnology Inc
  • Vicore Pharma AB
  • Yuhan Corp

薬剤プロファイル

I特発性肺線維症 - 休止中のプロジェクト

I特発性肺線維症 - 開発が中止された製品

I特発性肺線維症 - 製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

List of Tables

List of Tables

  • Number of Products under Development for Idiopathic Pulmonary Fibrosis, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Idiopathic Pulmonary Fibrosis - Pipeline by AbbVie Inc, 2021
  • Idiopathic Pulmonary Fibrosis - Pipeline by Abeome Corp, 2021
  • Idiopathic Pulmonary Fibrosis - Pipeline by Accendatech Co Ltd, 2021
  • Idiopathic Pulmonary Fibrosis - Pipeline by Accro BioScience (Suzhou) Co Ltd, 2021
  • Idiopathic Pulmonary Fibrosis - Pipeline by AdAlta Ltd, 2021
  • Idiopathic Pulmonary Fibrosis - Pipeline by Aeon Respire Inc, 2021
  • Idiopathic Pulmonary Fibrosis - Pipeline by Afimmune Biopharma Ltd, 2021
  • Idiopathic Pulmonary Fibrosis - Pipeline by Algernon Pharmaceuticals Inc, 2021
  • Idiopathic Pulmonary Fibrosis - Pipeline by Altavant Sciences Inc, 2021
  • Idiopathic Pulmonary Fibrosis - Pipeline by Altay Therapeutics Inc, 2021
  • Idiopathic Pulmonary Fibrosis - Pipeline by Aluda Pharmaceuticals Inc, 2021
  • Idiopathic Pulmonary Fibrosis - Pipeline by AmMax Bio Inc, 2021
  • Idiopathic Pulmonary Fibrosis - Pipeline by Amniotics AB, 2021
  • Idiopathic Pulmonary Fibrosis - Pipeline by Amplia Therapeutics Ltd, 2021
  • Idiopathic Pulmonary Fibrosis - Pipeline by AnaMar AB, 2021
  • Idiopathic Pulmonary Fibrosis - Pipeline by Angion Biomedica Corp, 2021
  • Idiopathic Pulmonary Fibrosis - Pipeline by Annji Pharmaceutical Co Ltd, 2021
  • Idiopathic Pulmonary Fibrosis - Dormant Projects, 2021
  • Idiopathic Pulmonary Fibrosis - Discontinued Products, 2021
  • Idiopathic Pulmonary Fibrosis - Discontinued Products, 2021 (Contd..1)

List of Figures

List of Figures

  • Number of Products under Development for Idiopathic Pulmonary Fibrosis, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Top 10 Routes of Administration, 2021
  • Number of Products by Stage and Top 10 Routes of Administration, 2021
  • Number of Products by Top 10 Molecule Types, 2021
  • Number of Products by Stage and Top 10 Molecule Types, 2021
目次
Product Code: GMDHC13057IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Idiopathic Pulmonary Fibrosis - Drugs In Development, 2021, provides an overview of the Idiopathic Pulmonary Fibrosis (Respiratory) pipeline landscape.Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease characterized by inflammation and scarring of lung tissue and loss of lung function. Symptoms of IPF include dry cough, shortness of breath, especially during or after physical activity, lasting tiredness and weight loss. Risk factors include smoking, environmental exposure, viral infections, family history and abnormal acid reflux. Treatment includes antioxidants, biological response modulators, anti-fibrotic agents and anticoagulants.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Idiopathic Pulmonary Fibrosis - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Idiopathic Pulmonary Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 7, 17, 45, 8, 123, 34 and 3 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 9 and 2 molecules, respectively.

Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Idiopathic Pulmonary Fibrosis (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

  • Introduction
  • Idiopathic Pulmonary Fibrosis - Overview
  • Idiopathic Pulmonary Fibrosis - Therapeutics Development
  • Idiopathic Pulmonary Fibrosis - Therapeutics Assessment
  • Idiopathic Pulmonary Fibrosis - Companies Involved in Therapeutics Development
  • Idiopathic Pulmonary Fibrosis - Drug Profiles
  • Idiopathic Pulmonary Fibrosis - Dormant Projects
  • Idiopathic Pulmonary Fibrosis - Discontinued Products
  • Idiopathic Pulmonary Fibrosis - Product Development Milestonesh
  • Appendix